Skip to main content
All lobbying filings

BRISTOL-MYERS SQUIBB COMPANY

Lobbying for BRISTOL-MYERS SQUIBB COMPANY

 Filing 1st Quarter - Report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 20, 2025
Expenses
$870,000.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 3
  • Centers For Medicare and Medicaid Services (CMS)
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 8
 Lobbying activity 5
Health Issues

Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 MINI Act ORPHAN Act Mental Health Appropriations Language FY26

Medicare/Medicaid

Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act

Taxation/Internal Revenue Code

Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation

Copyright/Patent/Trademark

Intellectual Property Reform concerning bio-pharmaceutical industry

Pharmacy

H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem